Tissue plasminogen activator mediates deleterious complement cascade activation in stroke.
The use of intravenous tissue plasminogen activator (tPA) in the treatment of ischemic stroke is limited by its propensity to exacerbate brain edema and hemorrhage. The mechanisms underlying these deleterious effects of tPA remain incompletely understood. The purpose of this study was to delineate a...
Main Authors: | Xue-Jun Zhao, Timothy M Larkin, Molly A Lauver, Saif Ahmad, Andrew F Ducruet |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2017-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC5507253?pdf=render |
Similar Items
-
Role of Tissue-Type Plasminogen Activator in Ischemic Stroke
by: Yasuhiro Suzuki
Published: (2010-01-01) -
Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
by: Latha Ganti, et al.
Published: (2022-02-01) -
Minor Role of Plasminogen in Complement Activation on Cell Surfaces.
by: Satu Hyvärinen, et al.
Published: (2015-01-01) -
Stroke thrombolysis: is tissue plasminogen activator a defibrillator for the brain?
by: Buchan, A, et al.
Published: (2000) -
Barriers to Receiving Tissue Plasminogen Activator in Patients with Ischemic Stroke
by: Monirsadat Mirzadeh, et al.
Published: (2021-04-01)